Caris Life Sciences (CAI) Other Non-Current Assets (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Other Non-Current Assets of $3.5 million for Q1 2026, down 14.67% year-over-year from $4.1 million in Q1 2025, and down 92.31% quarter-over-quarter from $45.3 million in Q4 2025.
Caris Life Sciences (CAI) Other Non-Current Assets (2024 - 2026) Analysis & Trends
Caris Life Sciences' Other Non-Current Assets history runs 3 years deep, the most recent figure standing at $3.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 14.67% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $3.5 million (down 14.67% YoY), while the FY2025 annual figure was $45.3 million, up 11.03% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $3.5 million, down from $45.3 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $47.0 million in Q3 2025, with the low at $3.5 million in Q1 2026.
- The 3-year median for Other Non-Current Assets is $41.0 million (2024), against an average of $30.3 million.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets grew 11.03% in 2025, then decreased 14.67% in 2026.
- Caris Life Sciences' Other Non-Current Assets stood at $40.8 million in 2024, then increased by 11.03% to $45.3 million in 2025, then plunged by 92.31% to $3.5 million in 2026.
- Business Quant data shows CAI's Other Non-Current Assets at $3.5 million in Q1 2026, $45.3 million in Q4 2025, and $47.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | 56.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.73 Mn |
| Mar 31, 2026 | 3.49 Mn |
| Dec 31, 2025 | 45.35 Mn |
| Sep 30, 2025 | 46.99 Mn |
| Jun 30, 2025 | 41.08 Mn |
| Mar 31, 2025 | 4.09 Mn |
| Dec 31, 2024 | 40.84 Mn |